^
Association details:
| Biomarker: | BRAF wild-type |
|---|---|
| Cancer: | Rectal Cancer |
| Drug: | Vectibix (panitumumab) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Rectal cancer: Systemic therapy for advanced or metastatic disease...FOLFOX + panitumumab (KRAS/NRAS/BRAF WT only)...FOLFIRI + panitumumab (KRAS/NRAS/BRAF WT only)...FOLFIRINOX or mFOLFIRINOX + panitumumab...Irinotecan + panitumumab (KRAS/NRAS/BRAF WT only)
Secondary therapy:
irinotecan; FOLFOX; FOLFIRI; FOLFIRINOX
